Literature DB >> 15019276

Distinct mechanisms are involved in tumoristatic and tumoricidal activities of monocyte-derived dendritic cells.

Nathalie Vanderheyde1, Peter Vandenabeele, Michel Goldman, Fabienne Willems.   

Abstract

Monocyte-derived dendritic cells (DC) were found to inhibit proliferation of different tumor cell lines. LPS-induced maturation of DC strongly increased their capacity to inhibit tumor cell growth. We observed that tumoristatic activity of LPS-activated DC was independent of their cytotoxic potential. Indeed, LPS-activated DC were able to inhibit growth of caspase-8-deficient or Bcl-2-overexpressing Jurkat cells whereas they were not cytotoxic towards the same targets. On the other hand, we found that supernatant derived from LPS-activated DC exerted a significant anti-proliferative activity against Jurkat cells while it did not induce any cytotoxic effect. Tumor necrosis factor (TNF) was shown to critically contribute to tumor growth inhibition in this system.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15019276     DOI: 10.1016/j.imlet.2003.11.011

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  8 in total

1.  Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFN-γ-dependent mechanism.

Authors:  Collin J LaCasse; Nona Janikashvili; Claire B Larmonier; Darya Alizadeh; Neale Hanke; Jessica Kartchner; Elaine Situ; Sara Centuori; Michael Har-Noy; Bernard Bonnotte; Emmanuel Katsanis; Nicolas Larmonier
Journal:  J Immunol       Date:  2011-11-09       Impact factor: 5.422

Review 2.  Innate lymphocyte and dendritic cell cross-talk: a key factor in the regulation of the immune response.

Authors:  A Reschner; P Hubert; P Delvenne; J Boniver; N Jacobs
Journal:  Clin Exp Immunol       Date:  2008-03-10       Impact factor: 4.330

3.  Cytotoxic dendritic cells generated from cancer patients.

Authors:  Daniela Lakomy; Nona Janikashvili; Jennifer Fraszczak; Malika Trad; Sylvain Audia; Maxime Samson; Marion Ciudad; Julien Vinit; Catherine Vergely; Denis Caillot; Pascal Foucher; Laurent Lagrost; Salem Chouaib; Emmanuel Katsanis; Nicolas Larmonier; Bernard Bonnotte
Journal:  J Immunol       Date:  2011-07-29       Impact factor: 5.422

4.  Near eradication of clinically relevant concentrations of human tumor cells by interferon-activated monocytes in vitro.

Authors:  Samuel Baron; Joel Finbloom; Julie Horowitz; Joseph Bekisz; Angel Morrow; Tongmao Zhao; Samuel Fey; Hana Schmeisser; Corey Balinsky; Kotaro Miyake; Christopher Clark; Kathryn Zoon
Journal:  J Interferon Cytokine Res       Date:  2011-02-16       Impact factor: 2.607

5.  A subset of myeloid dendritic cells derived from peripheral blood monocytes represented a predominant subset characterized by their potential tumor-inhibiting activity.

Authors:  Min Wang; Jun Shi; Yun Wan; Jing Li; Yinghua Yuan
Journal:  In Vitro Cell Dev Biol Anim       Date:  2009-03-14       Impact factor: 2.416

Review 6.  Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy.

Authors:  Neale Hanke; Darya Alizadeh; Emmanuel Katsanis; Nicolas Larmonier
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

7.  Macrophages and dendritic cells as actors in the immune reaction of classical Hodgkin lymphoma.

Authors:  Christiane Silke Tudor; Heiko Bruns; Christoph Daniel; Luitpold Valentin Distel; Arndt Hartmann; Armin Gerbitz; Maike Julia Buettner
Journal:  PLoS One       Date:  2014-12-03       Impact factor: 3.240

Review 8.  Tumoricidal activity of human dendritic cells.

Authors:  Jurjen Tel; Sébastien Anguille; Claire E J Waterborg; Evelien L Smits; Carl G Figdor; I Jolanda M de Vries
Journal:  Trends Immunol       Date:  2013-11-18       Impact factor: 16.687

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.